Yarrow Bioscience Inc. (YARW)
NASDAQ: YARWHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 2:52 PM ET
YARW stock chart
Technical analysisKey statistics
All statistics- Market cap
- $185.62M
- Dividend yield
- None
- Ex-dividend date
- Jul 24, 2026
- 52-week range
- 16.05 – 46.95
- Day range
- 18.34 – 20.09
- Volume / Avg
- 64.52K / 87.51K
- Beta
- —
- Shares outstanding
- 9.30M
- Next earnings
- Nov 5, 2026
52-week range
YARW stock today
On Oct 8, YARW is trading at $19.95, adding $1.18 (6.26%), versus the S&P 500's 0.58% decline. Shares are 57.5% below their 52-week high of $46.95, set on Jul 23, 2026 and 24.3% above the 52-week low of $16.05, near the bottom of the past year's range. YARW is down 35.3% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 7.5%.
Yarrow Bioscience's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Yarrow Bioscience
Company profileYarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Rebecca Velez Frey Pharm.D.
- Headquarters
- New York, NY
- Employees
- 7
- IPO year
- 2018
- Website
- yarrowbioscience.com
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$57.00+185.71%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $20.10
- Ex-dividend date
- Jul 24, 2026
Yarrow Bioscience peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ORMPOramed Pharmaceuticals Inc. | 4.20 | -3.89% | $174.71M | vs YARW |
| ANTXAN2 Therapeutics Inc. | 4.58 | -5.52% | $172.93M | vs YARW |
| DERMJourney Medical Corporation | 6.02 | +1.18% | $169.91M | vs YARW |
| PEPGPepGen Inc. | 2.39 | -0.42% | $165.31M | vs YARW |
| ADAGAdagene Inc. ADR | 2.75 | -2.14% | $184.64M | vs YARW |
| ALXOALX Oncology Holdings Inc. | 1.19 | +4.87% | $163.86M | vs YARW |
| CNTNCanton Strategic Holdings Inc. | 2.06 | -9.07% | $163.75M | vs YARW |
| CUECue Biopharma Inc. | 22.49 | -0.09% | $163.38M | vs YARW |
Indexes, lists and sector
Appears in lists
Yarrow Bioscience stock FAQ
What is Yarrow Bioscience's stock price today?
YARW last traded at $19.95 as of Oct 8, 2:52 PM EDT, up 6.26% on the day. Prices are delayed at least 15 minutes.
Does Yarrow Bioscience pay a dividend?
Yes. Yarrow Bioscience pays $0.00 per share annually. The most recent dividend of $20.10 had an ex-dividend date of Jul 24, 2026.
When is Yarrow Bioscience's next earnings date?
Yarrow Bioscience is expected to report earnings on Thursday, November 5, 2026.
Who is Yarrow Bioscience's CEO?
Ms. Rebecca Velez Frey Pharm.D. is the chief executive officer of Yarrow Bioscience Inc., which has about 7 employees.
Has YARW ever split its stock?
Yes. The most recent YARW stock split was a 1-for-50 split on Jul 27, 2026, one of 3 splits on record.
What is the YARW 52-week high?
The 52-week high for YARW is $46.95 and the 52-week low is $16.05. The stock is currently 57.5% below its high.